Common and Differentiated Representations Between Social Exclusion and Social Separation

Healthy Clinical Trial

Official title:

Common and Differentiated Representations Between Social Exclusion and Social Separation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05920707
• Other study ID #: UESTC-neuSCAN-93
• Status: Recruiting
• Phase: N/A
• Start date: April 20, 2023
• Est. completion date: October 1, 2023

Study information

• Verified date: June 2023
• Source: University of Electronic Science and Technology of China
• Contact: Keith M Kendrick, Dr
• Phone: +86-28-61830811
• Email: k.kendrick.uestc[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Explore the shared or separated neural mechanisms of social exclusion and social segregation and compare differential effects of AVP and OXT on these social interaction function.

Description:

A large body of research has shown that there are differences in the neural representation between social exclusion and social segregation, but the results are inconsistent, and the exploration of the neural basis is still insufficient. In addition, there are two mainstream theoretical explanations for these differences, namely the construction-level theory and the emotion-based theory, but there is no consistent theoretical model yet. Therefore, further exploration is necessary to confirm the cognitive and neural mechanisms underlying the differences between social exclusion and social segregation, and to attempt to reveal the theoretical explanations for these differences. In this project, the investigators propose to perform behavioral and functional magnetic resonance imaging (fMRI) techniques to examine the shared or separate neural mechanisms of social exclusion and social segregation (exp 1: social exclusion; exp 2: social separation) and investigate the modulatory effects of OXT/AVP on them (PLC/24IU OXT/20IU AVP).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: October 1, 2023
• Est. primary completion date: September 20, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

1. Healthy subjects;

2. Without any past or present psychiatric or neurological disorders;

3. Without any current psychotherapeutic medication.

EXclusion Criteria:

1. With any past or present psychiatric or neurological disorders;

2. With any current psychotherapeutic medication.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Intranasal Oxytocin
Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0. 1ml), three puffs per nostril one every 30 seconds.
• Intranasal Arginine Vasopressin
Administer arginine vasopressin (20 IU) intranasally, 6 individual 0.1 ml puffs (3.33 IU/0. 1ml), three puffs per nostril one every 30 seconds.
• Intranasal placebo
Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds.

Locations

Country	Name	City	State
China	University of Electronic Science and Technology of China(UESTC)	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
University of Electronic Science and Technology of China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neural index: OXT and AVP effects on fMRI based- social exclusion and social separation tasks	Comparions between OXT and AVP on social exclusion and social separation on brain activity or representations	45 minutes after treatment administration
Primary	Behavioral index: behavioral ratings of social exclusion and social separation tasks	Comparions between social exclusion and social separation in pain ratings	Immediately after fMRI scanning